|
|
Blood, 1 March 2007, Vol. 109, No. 5, pp. 2100-2105.
Prepublished online as a Blood First Edition Paper on November 9, 2006; DOI 10.1182/blood-2006-04-016360.
 Previous Article | Next Article 
Submitted April 11, 2006
Accepted October 16, 2006
Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma
Christian Jakob, Karl Egerer, Peter Liebisch, Seval Turkmen, Ivana Zavrski, Ulrike Kuckelkorn, Ulrike Heider, Martin Kaiser, Claudia Fleissner, Jan Sterz, Lorenz Kleeberg, Eugen Feist, Gerd R. Burmester, Peter M. Kloetzel, and Orhan Sezer*
Charite-Universitatsmedizin Berlin, Germany
University Hospital Ulm, Germany
* Corresponding author; email: sezer{at}charite.de.
The proteasome is a proteolytic complex for intracellular degradation of ubiquitinated proteins which are involved in cell cycle regulation and apoptosis. A constitutively increased proteasome activity has been found in myeloma cells. We studied circulating proteasome levels and their prognostic significance in sera of 50 controls, 20 individuals with monoclonal gammopathies of undetermined significance (MGUS) and 141 previously untreated patients with multiple myeloma (MM) by an anti-20S proteasome ELISA. Serum proteasome concentrations were significantly elevated in MM compared to controls (P < .001), in MM versus MGUS (P = .03) and in active (n=101) versus smouldering (n=40) MM (P < .001). In patients with active MM, there was a significant (P < .001) decrease from pre- to post-treatment proteasome concentrations in responders to chemotherapy, but not in nonresponders. Circulating proteasome levels were identified as a prognostic factor for overall survival in the univariate (log-rank: P < .001) and in the multivariate (hazard ratio 4.38) survival analysis in patients with active MM. We demonstrate for the first time that increased serum proteasome concentrations correlate with advanced disease and are an independent prognostic factor in MM.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Navon and A. Ciechanover
The 26 S Proteasome: From Basic Mechanisms to Drug Targeting
J. Biol. Chem.,
December 4, 2009;
284(49):
33713 - 33718.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. U. Sixt, M. Adamzik, D. Spyrka, B. Saul, J. Hakenbeck, J. Wohlschlaeger, U. Costabel, A. Kloss, J. Giesebrecht, B. Dahlmann, et al.
Alveolar Extracellular 20S Proteasome in Patients with Acute Respiratory Distress Syndrome
Am. J. Respir. Crit. Care Med.,
June 15, 2009;
179(12):
1098 - 1106.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L Henry, T Lavabre-Bertrand, L Vercambre, J Ramos, S Carillo, I Guiraud, P Pouderoux, M Bismuth, J-C Valats, C Demattei, et al.
Plasma proteasome level is a reliable early marker of malignant transformation of liver cirrhosis
Gut,
June 1, 2009;
58(6):
833 - 838.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Ma, H. Kantarjian, B. Bekele, A. C. Donahue, X. Zhang, Z. J. Zhang, S. O'Brien, E. Estey, Z. Estrov, J. Cortes, et al.
Proteasome Enzymatic Activities in Plasma as Risk Stratification of Patients with Acute Myeloid Leukemia and Advanced-Stage Myelodysplastic Syndrome
Clin. Cancer Res.,
June 1, 2009;
15(11):
3820 - 3826.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Sezer
Myeloma Bone Disease: Recent Advances in Biology, Diagnosis, and Treatment
Oncologist,
March 1, 2009;
14(3):
276 - 283.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Terpos, O. Sezer, P. Croucher, and M.-A. Dimopoulos
Myeloma bone disease and proteasome inhibition therapies
Blood,
August 15, 2007;
110(4):
1098 - 1104.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
